Curis (CRIS) has entered into an investigator-initiated clinical trial agreement with the University of Florida to study the combination of emavusertib and pembrolizumab in patients with metastatic melanoma. Curis is responsible for supply of emavusertib, Merck (MRK) is responsible for supply of pembrolizumab and clinical study costs. Both companies retain 100% of the commercial rights to their respective programs. The study is expected to begin enrollment in first half 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRIS:
- Biotech Alert: Searches spiking for these stocks today
- Curis trading resumes
- Curis trading halted, volatility trading pause
- Curis initiated with a Buy at Truist
- Curis reports Q3 EPS ($2.13), consensus ($2.33)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue